全球幹細胞市場分析（2010∼2025年） 是由出版商Visiongain在2010年05月所出版的。
這份英文市場調查報告書包含201 Pages 價格從美金2331起跳。
本報告書為幹細胞市場的概要與技術的、商業的潛力之相關檢驗，包含今後10年的研究開發與市場發展預測、短期、中期、長期的前景等等內容，概述如下。
第1章 總綱
第2章 幹細胞：導論
- 2010年之幹細胞：概要
- 幹細胞是什麼
- 幹細胞的潛力
- ES細胞
- 成人幹細胞
第3章 幹細胞對市場造成影響的課題：2010年
第4章 2010年幹細胞市場
- 幹細胞市場在2009年高達28億美元
- 幹細胞治療
- 幹細胞服務
- 血液銀行
第5章 新興幹細胞治療I：企業以及商務模式
- 幹細胞商務模式之探求
- 媒體所注目的幹細胞企業
- ES細胞
- 成人幹細胞治療：同種異系
- 成人幹細胞治療：自我移植
第6章 新興幹細胞治療II：適應
- 2025年為止的幹細胞成長動向
- 短期的適應
- 心血管疾病
- 腦・中樞神經疾病
- 成長期的器官
- 其他的適應
第7章 專家訪談
第8章 結論
圖表
Abstract
Report Details
-what commercial prospects for those technologies in medicine?
In 2010, the stem cells market stands on the brink of technological and
commercial breakthroughs, our new study explains. For the first time,
pharmaceutical companies are beginning to invest significantly in the drive to
create new treatments based on embryonic and adult stem cells. As this
research gathers pace, with clinical trials commencing, the potential of stem
cells in medicine may relatively soon be fulfilled. Results in animals
indicate that stem cells may provide treatment options for a range of
disorders and restorative applications including multiple sclerosis, diabetes,
Parkinson' s disease, Alzheimer' s disease, spinal cord injury, blindness,
immune system disorders and cardiovascular disease.
Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview
of this burgeoning sector, with technologies and commercial potential
discussed and forecasted. The sector will gather momentum as stem cell
therapies start to emerge from the R&D pipeline from this decade onwards. In
this report we assess the disease areas in which stem cell therapies are most
likely to emerge, with overviews of the commercial and academic research being
carried out in subsectors of healthcare. We analyse the short-, medium- and
long-term prospects for stem cell breakthroughs in disease areas, providing
the information that you require.
Our new report also provides a review of leading companies that currently seek
to harness stem cell technologies. The research areas of each company are
profiled, with discussion of the approaches being used. Some organisations are
developing scalable therapies with allogeneic stem cells, while others
investigate personalised treatments using autologous stem cells. Other
organisations pursue research in the embryonic stem cells field, which has
opened up in the US, with fewer obstacles and greater funding opportunities
available since 2009. Some companies already generate revenues from stem cells
by carving out market niches in stem cell supply, such as stem cells for drug
development and toxicity assays, or services such as stem cell banking in
umbilical cord blood. We analyse the main divisions of the market, providing
revenue forecasts for 2010 to 2025.
Comprehensive analysis of the global stem cells market
Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a
comprehensive review of information sources. We use primary and secondary
research. This report provides unique sales forecasts, market share analyses,
discussions of R&D pipeline developments and analyses of commercial drivers
and restraints, including SWOT analysis. There are comprehensive tables and
figures, as well as four interviews with experts. The result is a detailed
market- and industry-centred study, with analyses and informed opinion to
benefit your work.
Why you should buy Stem Cells - The Hype and the Hope 2010-2025
This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for stem cells
from 2010 to 2025, including predicted revenues, growth rates and other data
for the overall market and its main divisions
- You will find out where the market is heading - technologically and
commercially - from the present onwards, both for the global market and for
leading national markets
- You will discover prospects for leading companies and therapy areas, with
predictions of where main breakthroughs are likely to come from 2010 to 2025
- You will identify significant R&D developments as well as up-and-coming
technologies and products
- You will discover expert opinion from our interview-based survey, with
discussion of the present and future of stem cells in medicine
- You will assess the commercial drivers, restraints, competition and
opportunities influencing the global stem cell sector.
Our research shows that stem cells hold the potential to change medicine in
decades to come, with benefits to healthcare stakeholders starting to appear
during our forecast period, 2010 to 2025. We separate the real potential from
the wishful thinking in this complex field.
You can obtain this report today
Nobody with an interest in healthcare biotechnology should overlook our new
study on stem cells. We predict that revenue streams will commence and
increase during our forecast period. With rising demand for novel therapies
and many unmet clinical needs remaining, the stem cells industry and market
hold potential for high revenues and continuous innovation. Do you want to be
aware of those opportunities? You can stay ahead by ordering our new report
today.
Table of Contents
1. Executive Summary
- 1.1 Stem Cells Market Review
- 1.2 Crucial Aspects of the Stem Cells Market
- 1.3 Aims, Scope and Format of this Report
- 1.3.1 Speculative Aspects of Assessing the Stem Cell Field
- 1.3.2 Chapter Outline
- 1.4 Research and Analysis Methods
2. Stem Cells: An Introduction
- 2.1 Stem Cells in 2010: Overview of the Sector
- 2.2 The Basics: What Are Stem Cells?
- 2.3 Stem Cell Potency
- 2.3.1 Totipotency
- 2.3.2 Pluripotency
- 2.3.3 Multipotency
- 2.3.4 Oligopotency
- 2.3.5 Unipotency
- 2.3.6 Stem Cells and Progenitor Cells
- 2.4 Embryonic Stem Cells
- 2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells
- 2.4.2 Harvesting Human Eggs
- 2.5 Adult Stem Cells
- 2.5.1 Sources of Adult Stem Cells
3. Issues Affecting the Stem Cells Market, 2010
- 3.1 Strengths
- 3.1.1 Stem Cells Have Great Therapeutic Potential
- 3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease
- 3.1.3 Animal Models Yield Impressive Results
- 3.1.4 Stem Cells Already Have Some Therapeutic Applications
- 3.1.5 The Stem Cells Field Has Strength in Numbers
- 3.1.6 Discoveries Are Being Made at a Rapid Rate
- 3.1.7 Adult Stem Cells: Fewer Ethical Controversies
- 3.1.8 Many Governments Support Adult Stem Cell Research
- 3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their
Directly Therapeutic Applications
- 3.1.10 The Market Offers Multiple Business Models
- 3.2 Weaknesses
- 3.2.1 Therapies Take Time
- 3.2.2 Stem Cells and Cancer
- 3.2.3 The Safety-First Approach
- 3.2.4 Embryonic Stem Cell Supply Problems
- 3.2.5 Business Model Problems with Autologous Therapies
- 3.2.6 Donor Rejection Risk with Allogeneic Therapies
- 3.2.7 The Research Field is Fragmented
- 3.2.8 The IP Minefield
- 3.2.9 Government Money is Required: Little Venture Capital - Yet
- 3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells
- 3.3 Opportunities
- 3.3.1 Therapies: Almost Anything Could Happen
- 3.3.2 The Attractions of the Stem Cells Market
- 3.3.3 Asia Harnesses Stem Cells Opportunities
- 3.3.3.1 China: Favourable Regulations
- 3.3.3.2 Japan: Liberal hESC Policy
- 3.3.3.3 Singapore: Advanced and Prominent
- 3.3.3.4 South Korea: Stem Cells a National Priority
- 3.3.3.5 India: First Official Research Hub Opened in 2009
- 3.3.3.6 Israel: at The Forefront
- 3.3.3.7 Gulf Countries: Funding Stem Cell Research
- 3.3.4 Adipose Tissue Opportunities for IPSCs
- 3.3.5 Beyond Pluripotency
- 3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies
- 3.3.7 Unique Disease Modelling Possibilities With IPS Cells
- 3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital
- 3.3.9 The Opportunity to Get There First
- 3.3.10 Public Perception of Stem Cells Represents an Opportunity
- 3.4 Threats
- 3.4.1 The Risks of the Regulatory Environment
- 3.4.1.1 North America
- 3.4.1.2 Europe
- 3.4.2 Lack of Embryonic Stem Cell Diversity in US Research
- 3.4.3 Not Everyone Can Succeed in The Stem Cells Market
- 3.4.4 The Risk of Public Disenchantment
- 3.4.5 High-Profile Failures in Stem Cell Supply
- 3.4.6 High-Profile Failures in Stem Cell Therapies
- 3.4.7 Scare Stories and Perception Problems
- 3.4.8 Economic Instability
- 3.4.9 Market Fluidity is a Threat
- 3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals
Model?
4. The Stem Cell Market in 2010
- 4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009
- 4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010
- 4.2 Stem Cell Therapies
- 4.2.1 Existing Stem Cell Therapies Market
- 4.2.2 Diseases Treated With Adult Stem Cells In 2010
- 4.2.3 Bone Marrow Transplants
- 4.2.3.1 The Transplant Process
- 4.2.3.2 The Results
- 4.2.4. Peripheral Blood Stem Cell Transplants
- 4.2.5 Cord Blood Stem Cell Transplants
- 4.2.6 Allogeneic Transplants vs. Autologous Transplants
- 4.2.6.1 Allogeneic Transplants are Better for Killing Cancer
- 4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host
Disease and Host-versus-Graft Disease
- 4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen
to be a Saviour
- 4.2.6.4 UK Cases and Rules on Saviour Siblings
- 4.2.7 Other Surgery Involving Stem Cells
- 4.2.8 Osteocel and other Bone Regeneration Products
- 4.2.9 Stem Cells and Regenerative Medicine
- 4.2.9.1 Organogenesis
- 4.2.9.2 Stem Cell Therapeutics
- 4.2.9.3 CEL-SCI Corporation
- 4.2.9.4 Osteotech
- 4.2.9.5 RegeneRx
- 4.2.9.6 RTI Biologics
- 4.2.9.7 Biomimetic Therapeutics
- 4.2.9.8 Fibrocell
- 4.2.10 Stem Cell Cosmetics
- 4.2.10.1 Breast Enhancement
- 4.2.10.2 Topical "Stem Cell" Preparations
- 4.2.11 Unregulated Stem Cells Therapies
- 4.3 Stem Cell Services
- 4.3.1 The Market for Stem Cell Services
- 4.3.2 Some of the Companies in the Stem Cell Services Market
- 4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology
- 4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery
- 4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line
Bank
- 4.3.2.4 Axiogenesis: Research Tools
- 4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods
- 4.3.2.6 CellCyte Genetics: Expansion Bioreactor
- 4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines
- 4.3.2.8 Stemgent: Stem Cell Scientists
- 4.3.2.9 Regenetech: Stem Cell Expansion Leaders
- 4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines
- 4.3.2.11 Biotime: 200+ Patent Portfolio
- 4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?
- 4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform
- 4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture
Products
- 4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays
- 4.3.2.16 Stemride International Limited (SIL) and Reproductive
Genetics Institute, Chicago: Normal and Abnormal Cell Lines
- 4.3.2.17 ES Cell International, Singapore: Hoping for the First
Marketed Product Including Embryonic Stem Cells
- 4.3.2.18 StemCell Technologies: ES Cells and Cell Culture Supplies
- 4.3.2.19 Bio-Matrix Scientific Group: Cryopreservation
- 4.4 Blood Banking
- 4.4.1 Biological Insurance: Private Blood Banking
- 4.4.2 Umbilical Cord Banking: The Controversies
- 4.4.2.1 US Oversight of Cord Blood Stem Cells
- 4.4.3 The Market for Blood Banking
- 4.4.4 Companies in the Field
- 4.4.4.1 Cord Blood America: Looking Towards the Chinese Market
- 4.4.4.2 ViaCord: 145,000 Blood Units in Storage
- 4.4.4.3 Cryo-Cell International: The First Cord Blood Bank
- 4.4.4.4 Stem Cell Authority: Exclusive Stem Cells
- 4.4.4.5 LifebankUSA: Placenta-Cord Banking
5. The New Stem Cell Therapies I: Companies and Business Models
- 5.1 In Search of a Stem Cells Business Model
- 5.1.1 Embryonic or Adult?
- 5.2 Stem Cell Companies in the Media Spotlight
- 5.2.1 Towards the First Human Trials of Embryonic Stem Cells
- 5.2.2 Adult Stem Cells: Collaborations with Pharmaceutical Giants
- 5.3 Embryonic Stem Cells
- 5.3.1 Geron: First Embryonic Stem Cell Trial
- 5.3.1.1 Geron and GE Healthcare
- 5.3.2 Advanced Cell Technology (ACT)
- 5.3.2.1 Competition for ACT in Macular Degeneration Treatment
- 5.3.2.2 ACT Deals with Other Companies
- 5.3.3 Novocell: Looking to Follow Geron and ACT in Embryonic Stem Cells
Trials
- 5.3.3.1 Novocell' s Collaborations with Pharmaceutical Leaders
- 5.3.4 CellCure Neurosciences
- 5.3.5 Royan Institute (Tehran)
- 5.3.6 Reliance Life Sciences, India
- 5.4 Adult Stem Cell Therapies: Allogeneic
- 5.4.1 Osiris: First to Market with Stem Cells
- 5.4.1.1 Osiris and NuVasive
- 5.4.1.2 Osiris and Genzyme
- 5.4.1.3 Prochymal: Great Promise but How is Work Shaping Up?
- 5.4.1.4 What Next for Prochymal?
- 5.4.2 Athersys
- 5.4.2.1 Multistem: an Off-The-Shelf Allogeneic Stem Cell Therapy
- 5.4.3 StemCells
- 5.4.4 MediStem (MediStem Laboratories, Inc.)
- 5.4.5 ReNeuron
- 5.4.6 Pluristem Therapeutics
- 5.4.7 Amstem International (Stem Cell Therapy International/Histostem)
- 5.4.8 Neuralstem
- 5.4.9 Garnet BioTherapeutics/Neuronyx
- 5.4.10 HepaLife Technologies
- 5.5 Adult Stem Cells: Autologous Therapies
- 5.5.1 Opexa Therapeutics
- 5.5.2 Cellerix: Ontaril has EMEA Orphan Drug Status
- 5.5.3 Aastrom Biosciences
- 5.5.4 Bioheart
- 5.5.5 Cardiogenesis: Autologous Medical Devices
- 5.5.6 BrainStorm Cell Therapeutics
- 5.5.7 Cytori Therapeutics
- 5.5.8 TCA Cellular Therapy
- 5.5.9 Autologous Cell Storage
- 5.5.9.1 LifeStem: Two Sources of Stem Cells Preserved
- 5.5.9.2 Neostem: Success with Bone Marrow Stem Cell Storage
- 5.5.9.3 Thermogenesis: Autologous Cryopreservation
- 5.5.9.4 Biogenea-CellGenea: Leading Stem Cell Research Facility in the
EU
6. The New Stem Cell Therapies II: Indications
- 6.1 The Growth of the Stem Cells Market to 2025
- 6.2 Near-Term Indications
- 6.2.1 Cancer
- 6.2.1.1 Cancer Stem Cells
- 6.2.2 Immune Disorders
- 6.2.3 Eye Diseases
- 6.2.4 Orthopaedics
- 6.2.5 Diabetes
- 6.2.6 Other Likely Near-Term Indications
- 6.2.6.1 Acute Radiation Syndrome
- 6.3 Cardiovascular Diseases
- 6.4 Brain and Central Nervous System Diseases
- 6.4.1 Amyotrophic Lateral Sclerosis (ALS, Lou Gherig' s Disease)
- 6.4.2 Multiple Sclerosis
- 6.4.3 Alzheimer' s Disease
- 6.4.4 Cerebral Palsy
- 6.4.5 Pelizaeus-Merzbacher Disease (PMD)
- 6.4.6 Parkinson' s Disease
- 6.4.7 Spinal Cord Injury
- 6.5 Growing Organs
- 6.6 Other Possible Indications for Stem Cells
- 6.6.1 Autism
- 6.6.2 HIV and Other Viral Diseases
- 6.6.3 Fertility Treatment
7. Interviews with Experts
- 7.1 Dr Johan Luthman, Merck Serono
- 7.1.1 Difficulties of Translational Medicine
- 7.1.2 Differences Between Technology and Media Perceptions
- 7.1.3 Confusion in the Media
- 7.1.4 Stem Cells and Neurologic Disorders
- 7.1.4.1 Which Neurological Disorders will be Treated First?
- 7.1.4.2 Multiple Sclerosis
- 7.1.5 Why Stem Cell Results Take a Long Time
- 7.1.6 When Stem Cell Therapies Will Reach the Market
- 7.1.7 The Distinction between Regenerative Medicine and Stem Cell
Therapies
- 7.2 Dr Stephen Minger, Wolfson Centre for Age-Related Diseases, King' s
College London
- 7.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More
Funding/Support
- 7.2.2 Cord Blood and Embryonic Stem Cells
- 7.2.3 The Need for More Immunological Assays
- 7.2.4 How Long Until there are Human Stem Cell Therapies?
- 7.2.5 Cord Blood as a Source of Stem Cells
- 7.2.6 Private Cord Blood Banking
- 7.2.7 Therapeutic Cloning
- 7.2.7.1 Therapeutic Cloning and Tissue Type Cell Lines
- 7.2.8 Promising and Unusual Immunological Properties of Embryonic Stem
Cells
- 7.2.9 Mesenchymal Stem Cells and Inflammation
- 7.2.10 On the Use of Foreskin Fibroblasts
- 7.3 Gregory Bonfiglio, Proteus Venture Partners
- 7.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"
- 7.3.2 On "Near Term" Applications
- 7.3.3 Value-Creation Curve for Venture Capital in Stem Cells
- 7.3.4 On There Being No Known Limits on Stem Cell Possibilities
- 7.3.5 On Stem Cells in 25 Years
- 7.3.6 Funding as a Primary Limitation?
- 7.3.7 Stem Cells in Multiple Sclerosis and Diabetes Type 1
- 7.3.8 Cord Blood
- 7.3.9 Extracellular Matrixes
- 7.3.10 Disease-Specific Cell Lines
- 7.3.11 Adult vs. Embryonic Stem Cells
- 7.3.12 Capital for Stem Cell and Regenerative Medicine Research
- 7.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)
- 7.4.1 Embryonic Stem Cells and Dehumanisation
- 7.4.2 HFEA Regulation on Embryo Destruction
- 7.4.3 Economics and Scientific Effectiveness
- 7.4.4 Cord Blood
- 7.4.5 Adult Stem Cell Therapies and the Economics of Therapy
- 7.4.6 Public, Private and Private/Public Cord Blood Banks
- 7.4.7 International Studies and International Communication
8. Conclusions
- 8.1 The Stem Cell Market in 2010 is Small, But Will Grow Rapidly
- 8.2 The Stem Cell Therapies Market is on The Brink of Significant Growth
- 8.3 Induced Pluripotent Adult Stem Cells May Revolutionise the Market
- 8.4 The Sector Has Marked Uncertainties, But Many Opportunities
List of Tables
- Table 2.1 Potency and Source of Stem Cells
- Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
- Table 3.1 SWOT Analysis of the Stem Cells Sector, 2010
- Table 4.1 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
- Table 4.2 Some Diseases That Have Been Treated With Adult Stem Cells, 2010
- Table 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
- Table 4.4 Some Companies in the Regenerative Medicine Sector, 2010
- Table 4.5 Stem Cell Services: Sales Forecast ($m), 2010-2025
- Table 4.6 Some Companies in the Stem Cell Services Market, 2010
- Table 4.7 Cord Blood Banking: Sales Forecast ($m), 2010-2025
- Table 4.8 Some Companies in the Cord Blood Banking Market, 2010
- Table 5.1 Some Companies in the Embryonic Stem Cell Therapies Sector, 2010
- Table 5.2 Some Companies in the Allogeneic Adult Stem Cell Therapies
Sector, 2010
- Table 5.3 Some Companies in the Autologous Adult Stem Cell Therapies
Sector, 2010
- Table 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
- Table 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025
- Table 8.1 Total Stem Cells Market: Sales Forecast by Sector ($m), 2010-2025
List of Figures
- Figure 4.1 Sectors of the Stem Cells Market: Sales ($bn), 2009
- Figure 4.2 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
- Figure 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
- Figure 4.4 Stem Cell Services: Sales Forecast ($m), 2010-2025
- Figure 4.5 Cord Blood Banking: Sales Forecast ($m), 2010-2025
- Figure 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
- Figure 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025
Companies Listed
- Aastrom Biosciences
- Advanced Cell Technology
- Aldagen
- Alliance Technology Ventures
- Amorcyte
- AmStem International
- Angioblast Systems
- Anthony Nolan Trust
- Assisted Human Reproductions Agency
- AstraZeneca
- Athersys
- Australian Stem Cell Centre
- Axiogenesis
- AXM Pharma
- Biogenea-CellGenea
- Bioheart
- Bio-Matrix Scientific Group
- Biomimetic Therapeutics
- BioTime
- Boston Scientific Corporation
- BrainStorm Cell Therapeutics
- Bresagen
- Burnham Institute for Medical Research, University of California
- Calibochem
- Canadian Institute of Health
- Cardiogenesis Corp.
- Casey Eye Institute
- Cellartis
- CellCure Neurosciences
- CellCyte Genetics Corporation
- Cellerix
- Cellgene Corporation
- Cellular Dynamics International
- Cellular Engineering Technologies
- Celprogen
- CEL-SCI Corporation
- Centocor Ortho Biotech
- CHA Biotech
- Children' s Hospital of Orange County
- Children' s Hospital & Research Center in Oakland, California
- Cleveland Clinic
- Clinical Research Facility for Stem Cells and Regenerative Medicine,
Hyderabad
- Columbia University
- Comment on Reproductive Ethics (CORE)
- CorCell
- Cord Blood America
- Cord Blood Registry
- Cordon Vital (CBR)
- Cryo-Cell International
- CyThera
- Cytori Therapeutics
- Diostech
- Embryome Sciences
- ES Cell International (Singapore)
- European Medicines Agency (EMEA)
- European Union Group on Ethics (EGE), The
- EyeCyte
- Fate Therapeutics
- Fibrocell
- Fisher Scientific
- Foundation for Taxpayer and Consumer Rights, The
- Gamida Cell
- Garnet BioTherapeutics
- GE Healthcare
- Genzyme
- Geron Corporation
- Gladstone Institute of Cardiovascular Disease
- GlaxoSmithKline
- Hadasit Bio-Holdings
- Hadassah University Hospital
- Harvard Stem Cell Institute
- Harvard University
- HepaLife Technologies
- Histostem
- Human Fertilisation and Embryology Authority (HFEA, UK)
- HyClone
- Indiana University
- International Society of Stem Cell Research
- International Stem Cell Corporation
- iPS Cells
- Isolagen
- Israeli Health Ministry
- Johns Hopkins University
- Johnson & Johnson
- Korea Stem Cell Bank Co.
- LifebankUSA
- LifeCell India
- Lifeline Cell Technology
- LifeStem
- London Breast Institute, Princess Grace Hospital
- London Development Agency
- London Regenerative Medicine Network (LRMN)
- Maxim Biotech
- Mayo Clinic
- MedCell Biosciences
- Medical College of Georgia
- Medistem
- Merck & Co.
- Merck KGaA
- Merck Serono
- Mesoblast
- Multicell Technologies
- Muslim World League
- Mytogen
- NASA
- National Institutes of Health (NIH, US)
- National Health Service (NHS, UK)
- National Tissue Engineering Center (Shanghai)
- Neostem
- Neuralstem
- Neuronyx
- Northwestern University
- Novartis
- Novartis Institutes for BioMedical Research (NIBR)
- Novo Nordisk
- Novocell
- NuVasive
- Opexa Therapeutics
- Organogenesis
- Orthofix
- Osiris Therapeutics
- OST Developpement
- Osteotech
- Patient Patent Foundation
- Pfizer
- Pluristem Therapeutics
- Primogenix
- ProLife Alliance, The
- Proteus Venture Partners
- Purdue University Indianapolis
- Reeve-Irvine Research Centre
- Regenetech
- RegenRx
- Reliance Life Sciences, India
- ReNeuron
- Reproductive Genetics Institute (Chicago)
- RNL Bio
- Roche
- Royal Veterinary College, The
- Royan Institute (Tehran)
- RTI Biologics
- Rutgers University
- Safeguard Scientifics
- SCP Vitalife Partners
- Singapore Stem Cell Consortium
- Stanford University
- Stem Cell & Regenerative Medicine International
- Stem Cell Authority
- Stem Cell Innovations (SCI)
- Stem Cell Products
- Stem Cell Sciences
- Stem Cell Therapeutics Corp.
- Stem Cell Therapy International
- Stem Cells Research Forum of India (SCRFI)
- StemCell Technologies
- StemCells
- StemCells
- Stemgent
- StemLifeLine
- Stemride International Limited (SIL)
- SUNY Upstate Medical University
- Suzhou Erye Pharmaceuticals
- TCA Cellular Therapy
- Tengion
- Texas A&M University
- The Food and Drug Administration (FDA)
- Thermo Electron
- Thermo Fisher Scientific
- Thermogenesis Corp.
- Transition Holdings
- U.S. Army Institute of Surgical Research (USAISR)
- U.S. Department of Defense
- United States of America Patent and Trademark Office
- University College London
- University of Amsterdam
- University of California at Irvine
- University of California at San Diego
- University of Edinburgh
- University of Florida
- University of Helsinki
- University of Kyoto
- University of Miami
- University of Michigan
- University of Oklahoma
- University of Pittsburgh
- University of South Florida
- University of Texas, Medical Branch at Galveston
- University of Virginia
- University of Wisconsin
- UT Southwestern Medical Center
- Vantus
- Veritas Corporation
- VetCell Bioscience Limited
- VetStem
- ViaCord
- Vitro Biopharma
- Vitro Diagnostics
- Voss Laboratories
- Wake Forest University
- Wisconsin Alumni Research Foundation (WARF)
- Wolfson Centre for Age-Related Diseases (part of King' s College,
University of London)
|
